Vaginal Ecosystem and Network in the United States Study
NCT ID: NCT06472765
Last Updated: 2025-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
3250 participants
OBSERVATIONAL
2024-05-16
2028-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV)
NCT03769688
Transplantation of Vaginal Mikrobiome
NCT04855006
Effect of Flourish HEC Vaginal Care System on BV Recurrence and the Vaginal Microbiome
NCT05701722
Effects of Flourish HEC on Localized Provoked Vulvodynia
NCT05478746
Longitudinal Study of Vaginal Flora
NCT00340275
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A key aspect of this study is the creation of a registry that will compile the data obtained from the PCR/NGS test results and participant information. This registry will serve as a valuable resource for ongoing research and will support the development of personalized approaches in women's health care. By systematically collecting and analyzing data, the registry will facilitate a better understanding of the vaginal microbiome's role in health and disease, aiding in the advancement of diagnostic and therapeutic strategies.
Additionally, the registry will provide a foundation for future studies, allowing for the exploration of long-term trends and relationships within the vaginal microbiome. This could lead to new insights into how the microbiome influences gynecological health and the development of targeted treatments. The combination of validating a precise diagnostic tool and establishing a comprehensive registry is aimed at enhancing patient care and supporting the broader research community in women's health.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Premenopausal Healthy
Premenopausal Healthy
Vaginal Swab Collection
Vaginal Swab Collection
Perimenopausal Healthy
Perimenopausal Healthy
Vaginal Swab Collection
Vaginal Swab Collection
Postmenopausal Healthy
Postmenopausal Healthy
Vaginal Swab Collection
Vaginal Swab Collection
Bacterial Vaginosis
Bacterial Vaginosis
Vaginal Swab Collection
Vaginal Swab Collection
Candidiasis
Yeast Infections
Vaginal Swab Collection
Vaginal Swab Collection
Urinary Tract Infection
Premenopausal and Postmenopausal Women
Vaginal Swab Collection
Vaginal Swab Collection
Genitourinary Syndrome of Menopause
Vaginal Atrophy
Vaginal Swab Collection
Vaginal Swab Collection
Lichen Sclerosus/Planus
Lichen Sclerosus/Planus
Vaginal Swab Collection
Vaginal Swab Collection
Vulvodynia
Vulvodynia
Vaginal Swab Collection
Vaginal Swab Collection
Endometriosis
Endometriosis
Vaginal Swab Collection
Vaginal Swab Collection
Ureaplasma
Ureaplasma
Vaginal Swab Collection
Vaginal Swab Collection
Desquamative Inflammatory Vaginitis (DIV)
Desquamative Inflammatory Vaginitis (DIV)
Vaginal Swab Collection
Vaginal Swab Collection
Cancer
Group 1: Breast cancer patients diagnosed at stages 1-3, post-menopausal (due to surgical, chemical reasons, or age-related natural processes), and currently receiving anti-estrogen treatment for a minimum of 90 days.
Group 2: Breast cancer patients diagnosed at stages 1-3, pre-menopausal, and undergoing anti-estrogen endocrine therapy for at least 90 days.
Group 3: Participants diagnosed with any type of cancer at stages 1-3, not receiving anti-estrogen therapy, but have been using vaginal estrogen, prasterone, or DHEA for 90 days or more. Should not be on systemic hormone replacement therapy (estrogen with or without progesterone).
Group 4: Diagnosed with any type of cancer at stages 1-3, and should not be receiving any anti-estrogen therapy or using vaginal estrogen, prasterone, or DHEA. These individuals must not be on systemic hormone replacement therapy.
Group 5: Participants diagnosed at stage 4
Vaginal Swab Collection
Vaginal Swab Collection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vaginal Swab Collection
Vaginal Swab Collection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
89 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vaginal Biome Science
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kimberly Capone, PhD
Role: PRINCIPAL_INVESTIGATOR
Vaginal Biome Science
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women's Pelvic Health Center
Fullerton, California, United States
Claris Health
Los Angeles, California, United States
University of California Los Angeles Department of Radiation Oncology
Los Angeles, California, United States
Pelvic Pain Rehab
Pasadena, California, United States
Healthy Mothers, Healthy Babies Coalition of Hawaii
Honolulu, Hawaii, United States
Rachel Rubin MD PLLC
Bethesda, Maryland, United States
Dr. Christina Enzmann at Easton Advanced Aesthetics and Regenerative Medicine
Easton, Maryland, United States
Empowered Midwifery and Wellness LLC
Alexandria, Minnesota, United States
Xena Health
Henderson, Nevada, United States
Empire OBGYN
Kenmore, New York, United States
Gary H Goldman, MD
New York, New York, United States
Camel City Women's Wellness
Winston-Salem, North Carolina, United States
UH Hospitals
Mayfield Heights, Ohio, United States
Northwest Obstetrics and Gynecology
Oklahoma City, Oklahoma, United States
Haven Center for Sexual Medicine & Vulvovaginal Disorders
Tulsa, Oklahoma, United States
Center of the Health
Corvallis, Oregon, United States
Amber Wellness Group
Portland, Oregon, United States
Center for Pelvic Medicine
Bryn Mawr, Pennsylvania, United States
North Houston Gynecologic Oncology Surgeons, PLLC
Shenandoah, Texas, United States
Hello Climax
Virginia Beach, Virginia, United States
Integrative Naturopathic Medical Centre
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CRVA2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.